Literature DB >> 15886275

PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose.

U Panchapakesan1, S Sumual, C A Pollock, X Chen.   

Abstract

Peroxisome proliferator-activated receptor-gamma (PPARgamma) are ligand-activated transcription factors that regulate cell growth, inflammation, lipid metabolism, and insulin sensitivity. We recently demonstrated that PPARgamma agonists limit high glucose-induced inflammation in a model of proximal tubular cells (PTC; Panchapakesan U, Pollock CA, and Chen XM. Am J Physiol Renal Physiol 287: F528-F534, 2004). However, the role of PPARgamma in the excess extracellular matrix production is largely unknown. We evaluated the effect of 24- to 48-h 8 microM l-805645 or 10 microM pioglitazone on 25 mM D-glucose-induced markers of fibrosis in HK-2 cells. High D-glucose induced nuclear binding of activator protein-1 (AP-1) to 140.8 +/- 10.9% (P < 0.05), which was attenuated with L-805645 and pioglitazone to 82.3 +/- 14.4 (P < 0.01 vs. high D-glucose) and 99.3 +/- 12.2% (P < 0.05 vs. high D-glucose), respectively. High D-glucose increased total production of transforming growth factor (TGF)-beta(1) 139.6 +/- 6.5% (P < 0.05), which was reversed with L-805645 and pioglitazone to 68.73 +/- 5.7 (P < 0.01 vs. high D-glucose) and 112 +/- 13.6% (P < 0.05 vs. high D-glucose). L-805645 and pioglitazone reduced high d-glucose-induced fibronectin from 156.0 +/- 24.9 (P < 0.05) to 81.9 +/- 16.0 and 57.4 +/- 12.7%, respectively (both P < 0.01 vs. high D-glucose). Collagen IV was not induced by high d-glucose. L-805645 and pioglitazone suppressed collagen IV to 68.0 +/- 14.5 (P < 0.05) and 46.5 +/- 11.6% (P < 0.01) vs. high D-glucose, respectively. High D-glucose increased the nuclear binding of NF-kappaB to 167 +/- 22.4% (P < 0.05), which was not modified with PPARgamma agonists. In conclusion, PPARgamma agonists exert antifibrotic effects in human PTC in high glucose by attenuating the increase in AP-1, TGF-beta(1), and the downstream production of the extracellular matrix protein fibronectin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15886275     DOI: 10.1152/ajprenal.00097.2005

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  39 in total

1.  Strategy for the development of a matched set of transport-competent, angiotensin receptor-deficient proximal tubule cell lines.

Authors:  Philip G Woost; Robert J Kolb; Margaret Finesilver; Irene Mackraj; Hans Imboden; Thomas M Coffman; Ulrich Hopfer
Journal:  In Vitro Cell Dev Biol Anim       Date:  2006 Jul-Aug       Impact factor: 2.416

Review 2.  Involvement of PPAR nuclear receptors in tissue injury and wound repair.

Authors:  Liliane Michalik; Walter Wahli
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

Review 3.  Peroxisome proliferator-activated receptors ligands and ischemia-reperfusion injury.

Authors:  Rosanna Di Paola; Salvatore Cuzzocrea
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-03-13       Impact factor: 3.000

4.  Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI.

Authors:  Tayeba Khan; Eric S Muise; Puneeth Iyengar; Zhao V Wang; Manisha Chandalia; Nicola Abate; Bei B Zhang; Paolo Bonaldo; Streamson Chua; Philipp E Scherer
Journal:  Mol Cell Biol       Date:  2008-12-29       Impact factor: 4.272

5.  Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.

Authors:  Melanie S Joy; Debbie S Gipson; Mary Dike; Leslie Powell; Amber Thompson; Suzanne Vento; Allison Eddy; Agnes B Fogo; Jeffrey B Kopp; Daniel Cattran; Howard Trachtman
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 8.237

6.  Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus.

Authors:  Jorge E Toblli; Monica G Ferrini; Gabriel Cao; Dolores Vernet; Margarita Angerosa; Nestor F Gonzalez-Cadavid
Journal:  Nephrol Dial Transplant       Date:  2009-03-17       Impact factor: 5.992

7.  PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis.

Authors:  Jami E Milam; Venkateshwar G Keshamouni; Sem H Phan; Biao Hu; Srinivasa R Gangireddy; Cory M Hogaboam; Theodore J Standiford; Victor J Thannickal; Raju C Reddy
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-12-27       Impact factor: 5.464

8.  Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts.

Authors:  G-H Hao; X-L Niu; D-F Gao; J Wei; N-P Wang
Journal:  Br J Pharmacol       Date:  2008-02-18       Impact factor: 8.739

Review 9.  Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study.

Authors:  Prasad Bichu; Ravi Nistala; Asma Khan; James R Sowers; Adam Whaley-Connell
Journal:  Vasc Health Risk Manag       Date:  2009-04-08

10.  PPARgamma agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis.

Authors:  Jee-Young Han; Ye-Ji Kim; Lucia Kim; Suk-Jin Choi; In-Suh Park; Joon-Mee Kim; Young Chae Chu; Dae-Ryong Cha
Journal:  J Korean Med Sci       Date:  2009-12-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.